Literature DB >> 10384915

Expression of p53 protein before and after PUVA treatment in psoriasis.

A Hannuksela-Svahn1, P Pääkkö, P Autio, T Reunala, J Karvonen, K Vähäkangas.   

Abstract

We investigated the effect of the potentially carcinogenic psoralen plus UVA radiation (PUVA) therapy on the expression of p53 in skin of psoriatic patients. p53 antibodies DO7 and Pab240, antibodies against PCNA and Ki67 and the avidin-biotin immunoperoxidase complex method were used in the immunohistochemical staining of biopsy samples from non-lesional and lesional skin of 23 patients who received either trioxsalen bath PUVA or oral 8-methoxypsoralen PUVA. Biopsies were taken before and after a PUVA course. A modest expression of p53 was seen in psoriatic lesions in 17/21 patients before any treatment, probably as a physiological reaction to the hyperproliferation. Both p53 and the proliferation markers Ki67 and PCNA followed the same pattern, being more frequent in psoriatic lesions than in non-lesional skin. Exposure to PUVA induced an increase in p53 expression in non-lesional skin in 14/19 patients, putatively as a response to DNA damage caused by PUVA. In psoriatic lesions about half of the patients showed increased and half decreased expression of p53. The latter finding might be explained by decreased proliferation activity of the healing epidermis. In conclusion, p53 nuclear positivity in non-lesional skin after PUVA treatment is likely to be induced by DNA damage caused by PUVA, while in psoriatic lesions it could be a result of the combined effect of decreasing epidermal proliferation and DNA-damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10384915     DOI: 10.1080/000155599750010959

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  6 in total

1.  Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis.

Authors:  Peter Wolf; Dat X Nghiem; Jeffrey P Walterscheid; Scott Byrne; Yumi Matsumura; Yasuhiro Matsumura; Cora Bucana; Honnavara N Ananthaswamy; Stephen E Ullrich
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

2.  p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage.

Authors:  G Salvador; R Sanmarti; A Garcia-Peiró; J R Rodríguez-Cros; J Muñoz-Gómez; J D Cañete
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

3.  Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome.

Authors:  Gunter Assmann; Annette D Wagner; Mueller Monika; Claudia Pfoehler; Michael Pfreundschuh; Wolfgang Tilgen; Klaus Roemer
Journal:  Rheumatol Int       Date:  2009-09-25       Impact factor: 2.631

4.  Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.

Authors:  Carine Robert; Pratik K Nagaria; Nisha Pawar; Adeoluwa Adewuyi; Ivana Gojo; David J Meyers; Philip A Cole; Feyruz V Rassool
Journal:  Leuk Res       Date:  2016-03-30       Impact factor: 3.156

5.  Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.

Authors:  Christopher Butt; Lynette Peddle; Celia Greenwood; Sean Hamilton; Dafna Gladman; Proton Rahman
Journal:  Arthritis Res Ther       Date:  2006-01-03       Impact factor: 5.156

6.  Apoptosis and clinical severity in patients with psoriasis and HCV infection.

Authors:  Sami A Gabr; Mohamed Y Berika; Ahmad H Alghadir
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.